N2off, INC 8-K filings

Nexentis Technologies Inc. announced a $1.25 million capital raise through a registered direct offering of common stock and a concurrent private placement of warrants.

Nexentis Technologies Inc. has amended its credit facility with L.I.A. Pure Capital Ltd., increasing the total available financing to EUR 10,000,000 and modifying warrant terms.

Nexentis Technologies stockholders approved key proposals including reverse stock split authority and equity issuance.

Nexentis Technologies Inc. will implement a 1-for-7 reverse stock split effective April 7, 2026, to consolidate its outstanding common shares.

Nexentis Technologies Inc. has completed the transfer of its 98% stake in Save Foods Ltd. to Voice Assist, Inc., receiving a 19.99% equity interest in Voice Assist and entering into a services agreement.

Nexentis Technologies Inc. issued 600,000 common shares to consultants for investor relations and business development services.

N2OFF, Inc. announces a corporate rebranding to Nexentis Technologies Inc. and a strategic pivot to an AI and data-driven computational biotech platform.

N2OFF, Inc. has entered into an agreement to divest its 98% stake in Save Foods Ltd. to Voice Assist, Inc. in exchange for a 19.99% equity stake in Voice Assist and future service-based considerations.

N2OFF, Inc. issued 35,000 shares of common stock to a consultant for investor relations services, exempt from public registration.

N2OFF, Inc. announced the issuance of 60,000 common shares for investor relations services and reported shareholder approval of all proposals at its annual general meeting, including director re-elections and an amendment to its share incentive plan.

N2OFF, Inc. has acquired MitoCareX Bio, a drug discovery company focused on developing cancer therapeutics for Non-Small Cell Lung Cancer by targeting mitochondrial carrier proteins.

N2OFF, a cleantech company, has finalized its acquisition of MitoCareX Bio Ltd., marking its entry into the drug discovery market for resistant cancers.

N2OFF, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance notice.

N2OFF, Inc. stockholders approved the acquisition of MitoCareX Bio Ltd., a drug discovery company targeting resistant cancers, alongside a reverse stock split authorization and warrant issuance.

N2OFF, Inc. will implement a 1-for-35 reverse stock split effective September 22, 2025, to regain Nasdaq compliance and attract institutional investors.

N2OFF, Inc. announced additional funding for a battery storage study and the effectiveness of a 1-for-35 reverse stock split.

N2OFF, Inc. has provided a $372,000 loan to MitoCareX Bio Ltd. to finance its operations ahead of a planned acquisition, subject to N2OFF shareholder approval.

N2OFF, Inc. has received the initial $1.5 million tranche of a previously announced $3 million advance from YA II PN, Ltd., evidenced by a new promissory note.

N2OFF, Inc. amended its Purchase Agreement with YA II PN, Ltd. to secure an additional $3 million in funding and revise promissory note payment terms.

N2OFF, Inc. has further amended its Securities Purchase and Exchange Agreement for the MitoCareX Bio Ltd. acquisition, adjusting seller allocations, updating share counts, and extending the closing deadline by 90 days.

N2OFF, Inc. extends the exclusivity period for its acquisition of MitoCareX Bio Ltd. and provides an additional $250,000 loan to support MitoCareX's ongoing operations.

N2OFF, Inc. has entered into a purchase agreement with YA II PN, LTD. for a $3 million financing to support the company's strategic objectives.

N2OFF, Inc. issued a total of 4,400,000 shares of common stock to consultants and executives on May 12, 2025, for services rendered.

N2OFF, Inc. divests its entire stake in NTWO OFF Ltd. to Yaaran Investments Ltd. for 15,000 New Israeli Shekels, relinquishing board representation and nullifying a prior share exchange agreement.

N2OFF, Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting if the share price doesn't recover.

N2OFF Inc. amended its Securities Purchase Agreement to increase the beneficial ownership limitation from 4.99% to 9.99% of the company's outstanding capital stock.

N2OFF, Inc. has entered into a loan agreement to provide $250,000 to MitoCareX Bio Ltd., with L.I.A. Pure Capital Ltd. guaranteeing the repayment.

N2OFF, Inc. has executed a preliminary agreement to acquire a 70% stake in SB Impact 4 LTD, investing in two battery storage projects in Sicily, Italy, and providing a loan of Euro 2.3 million.

N2OFF, a clean tech company, has signed a definitive agreement to acquire MitoCareX Bio, a drug discovery company targeting resistant cancers, marking its entry into the biotech sector.

N2OFF, Inc. has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.